leadf
logo-loader
viewAnglo American PLC

Anglo American “well positioned” says Goldman, but analysts downgrade to ‘neutral’ on valuation grounds

The US bank said the blue-chip miner’s current share price level, which has risen around 26% after hitting a six-month low in August, better reflected their forecast returns profile

Anglo American plc - Anglo American “well positioned” says Goldman, but analysts downgrade to ‘neutral’ on valuation grounds
Goldman added that there is a risk Anglo may not be able to secure a licence to expand a tailings dam at its Minas Rio mine in Brazil

Anglo American plc (LON:AAL) is “well positioned” in the current commodities cycle, according to analysts at Goldman Sachs, however, the bank downgraded the firm to ‘neutral’ from ‘buy’ on valuation grounds following a recent rise in the shares.

The US bank, which also trimmed its target price to 2,200p from 2,300p, said the blue-chip miner’s current share price level, which has risen around 26% after hitting a six-month low in August, better reflected their forecast returns profile and that the risk-reward was now “more balanced”.

READ: Anglo American's copper production dries up in severe drought

“With the strength of [platinum group metals] prices (palladium >US$1,700/oz, rhodium c.US$5,000/oz) and known weakness in diamonds…we now see limited scope for upward revisions to 2020 consensus EBITDA expectations”, Goldman said.

They added that there is a risk that Anglo may not be able to secure an operating licence to expand a tailings dam at its Minas Rio iron ore mine in Brazil, a requirement for the site to reach full capacity.

Without the licence, analysts said Minas would run “at a reduced capacity” in 2020 which would be negative for the share price.

Despite the somewhat neutral assessment, Anglo’s shares rose 1.7% to 2,106.1p, a 4.3% discount to Goldman’s new target price.

Quick facts: Anglo American PLC

Price: 1866.4 GBX

LSE:AAL
Market: LSE
Market Cap: £254.42 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO plays 'pivotal role' after announcing £2m extension to Huntington's...

IXICO PLC's (LON:IXI) Lammert Albert talks to Proactive London about the £2m extension to a contract to provide additional imaging services for a pivotal Huntington's disease (HD) study. Albert describes this as a 'strong suit' having started very early and now carrying out a Phase III study...

29 minutes ago

2 min read